NDAORALTABLETPriority Review
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Mechanism of Action
[see Microbiology ()] .
Indications (6)
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus speciesthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coliProteus mirabilisEnterococcus faecalisthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp